

DYNAVAX TECHNOLOGIES CORP

Form 8-K

November 14, 2006

TABLE OF CONTENTS

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

INDEX TO EXHIBITS

EXHIBIT 99.1

Table of Contents

Item 8.01. Other Events.

In a press release dated November 12, 2006, the Company announced additional data from a Phase 2b study involving its TOLAMBA investigational therapy.

The press release dated November 12, 2006, titled Dynavax Reports New TOLAMBA Data at ACAAI Meeting, is attached hereto as Exhibit 99.1 and is herein incorporated by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated November 12, 2006, entitled Dynavax Reports New TOLAMBA Data at ACAAI Meeting.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dynavax Technologies Corporation

Dated: November 13, 2006

By: /s/ Deborah A. Smeltzer
Deborah A. Smeltzer, Vice President,
Operations and Chief Financial Officer

Table of Contents

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press Release, dated November 12, 2006, entitled Dynavax Reports New TOLAMBA Data at ACAAI Meeting.